Organofosfat Zehirlenmesi Olan Kritik Hastalarda Plazmaferez ve Standart Tedavinin Serum Psödokolinesteraz ve Eritrosit Asetilkolinesteraz Düzeyleri Üzerindeki Etkisinin Standart Tedavi ile Karşılaştırılması: Randomize Kontrollü, Açık Etiketli, Klinik Çalışma

Year 2023, Volume: 5 Issue: 3, 209 - 215, 10.10.2023

Gülten Can Sezgin Hilal Sipahioğlu Kürşat Gündoğan Ramazan Coşkun Şahin Temel Cevat Yazıcı Okhan Akdur Murat Sungur Muhammet Güven

https://doi.org/10.52827/hititmedj.1326182

Abstract

Amaç: Organofosfatlar dünya çapında yaygın olarak kullanılan insektisitlerdir. Organofosfat zehirlenmelerinde yetersiz tedavi morbidite ve mortaliteyi artırmaktadır. Çalışmanın amacı, organofosfat zehirlenmesi olan ciddi hastalarda serum psödo-kolinesteraz ve eritrosit asetil kolinesteraz düzeyleri üzerinde standart tedaviye karşı, standart tedavi artı plazmaferezin etkinliğini araştırmaktır.
Materyal ve Method: Bu araştırma prospektif bir çalışmadır. Çalışmaya organofosfat zehirlenmesi tanısı alan hastalar dahil edildi. Hastalar müdahale grubu ve standart grup olarak iki gruba ayrıldı. Müdahale grubuna standart tedaviye ek olarak plazmaferez tedavisi uygulandı.
Bulgular: Çalışmaya kırk hasta alınmıştır (müdahale grubu n:21, standart grup n:19). Başlangıçta serum psödo-kolinesteraz değerleri 482,5 u/L, plazmaferez sonrası 3723 u/L idi. Eritrosit asetil kolinesteraz değerleri başvuruda 1,91 u/mL, plazmaferez sonrası 2,53 u/mL idi. Eritrosit asetil kolinesteraz ve serum psödo-kolinesteraz değerleri hastaların yoğun bakıma kabulünden itibaren ilk 5 gün ve yoğun bakımdaki son gün değerleri iki grup arasında karşılaştırıldı. İki grup arasında 2. gün dışında istatistiksel fark yoktu (p> 0.05). Her iki grubun ikinci gün karşılaştırmasında psödo-kolinesteraz değerleri arasında istatistiksel olarak anlamlı fark olduğu görüldü (p=0,028).
Sonuç: Sonuç olarak, plazmaferez tedavisi psödo-kolinesteraz düzeyine olumlu katkı sağlayabilir. Bu tedavi organofosfatların vücuttan atılması için ek süre sağlamış olabilir. Asetil kolinesteraz reaktivasyonu oksim tedavisi ile sağlansa da bu tedavinin klinik etkisi net değildir.

Keywords

Organophosphate poisoning, erythrocyte acetyl cholinesterase, pseudo-cholinesterase, plasmapheresis, ICU.

Project Number

Project no: TT-07-27, Gulten Can Sezgin

Effects of Standard Treatment Alone Versus Standard Treatment plus Plasmapheresis on the Levels of Serum Pseudocholinesterase and Erythrocyte Acetylcholinesterase in Critically Patients with Organophosphate Poisoning: Randomized Controlled, Open-label, Clinical Trial

Abstract

Objective: Organophosphates are the insecticides commonly used worldwide. Inadequate treatment in organophosphates poisoning increases morbidity, and mortality. Purpose of the work was to determine the effect of standard treatment alone versus standard treatment plus plasmapheresis on the levels of serum pseudo-cholinesterase, and erythrocyte acetyl cholinesterase in severe patients with organophosphates poisoning.
Material and Method: This research is a prospective study. Patients diagnosed with organophosphates poisoning were included in the work. The patients were divided into two groups as the intervention group, and the standard group. The intervention group, plasmapheresis was performed in addition to the standard treatment.
Results: The research was conducted with forty cases. (Intervention group n:21, standard group n:19). Serum pseudo-cholinesterase values were 482.5 u/L at baseline, 3723 u/L after plasmapheresis. Erythrocyte acetyl cholinesterase values were 1.91 u/mL on admission, 2.53 u/mL after plasmapheresis. Erythrocyte acetyl cholinesterase and serum pseudo-cholinesterase values were compared between the two groups daily from the admission of patients to intensive care units during the first 5 days, and on the last day in the intensive care units. There was no statistical difference between two groups (p> 0.05), except for the second day. It was observed that there was a statistically significant difference between the pseudo-cholinesterase values in the second day comparison of both groups (p=0.028).
Conclusion: In conclusion, plasmapheresis treatment may contribute positively to pseudo-cholinesterase level. This treatment may have provided additional time for the organophosphates to be eliminated from the body. Although acetyl cholinesterase reactivation is achieved with oxime treatment, the clinical effect of this treatment is not clear.

Keywords

Erythrocyte acetyl cholinesterase, intensive care units, Organophosphate poisoning, plasmapheresis, pseudo-cholinesterase.

Supporting Institution

This study was supported by Erciyes University Scientific Research Committee.

Project Number

Project no: TT-07-27, Gulten Can Sezgin

References

• Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet (London, England). 2008; 371(9612): 597-607.
• Sungur M, Guven M. Intensive care management of organophosphate insecticide poisoning. Critical care (London, England). 2001; 5(4): 211-5.
• Coskun R, Gundogan K, Sezgin GC, et al. A retrospective review of intensive care management of organophosphate insecticide poisoning: Single center experience. Nigerian journal of clinical practice. 2015; 18(5): 644-50.
• Ozturk MA, Kelestimur F, Kurtoglu S, Guven K, Arslan D. Anticholinesterase poisoning in Turkey--clinical, laboratory and radiologic evaluation of 269 cases. Human & experimental toxicology. 1990; 9(5): 273-9.
• Guven M, Unluhizarci K, Goktas Z, Kurtoglu S. Intravenous organophosphate injection: an unusual way of intoxication. Human & experimental toxicology. 1997; 16(5): 279-80.
• Simsek ZO, Simsek Y, Sungur M, Gundogan K, Guven M. Effects of Organophosphate Poisoning on Endocrine System in Long-Term: A Pilot Study. Erciyes Med J. 2019.
• Selim K. Acute and Long-term Effects of Organophosphate Poisoning. Erciyes Medical Journal. 2019; 41(1): 3-4.
• Guven M, Sungur M, Eser B. The effect of plasmapheresis on plasma cholinesterase levels in a patient with organophosphate poisoning. Human & experimental toxicology. 2004; 23(7): 365-8.
• Guven M, Sungur M, Eser B, Sari I, Altuntas F. The effects of fresh frozen plasma on cholinesterase levels and outcomes in patients with organophosphate poisoning. Journal of toxicology Clinical toxicology. 2004; 42(5): 617-23.
• Disel NR, Acikalin A, Kekec Z, Sebe A. Utilization of plasmapheresis for organophosphate intoxication: A case report. Turkish journal of emergency medicine. 2016; 16(2): 69-71.
• Yukselmis U, Ozcetin M, Cag Y, Yildizdas D, Yilmaz HL. The role of plasmapheresis in organophosphate poisoning: Case reports of three pediatric patients. The Turkish journal of pediatrics. 2017; 59(4): 491-6.
• Dayananda VP, Bhaskara B, Pateel GN. A study of effectiveness of fresh frozen plasma in organophosphorous compound poisoning in reducing length of Intensive Care Unit stay and in reducing need for tracheostomy. Anesthesia, essays and researches. 2016; 10(2): 268-72.
• Brahmi N, Mokline A, Kouraichi N, et al. Prognostic value of human erythrocyte acetyl cholinesterase in acute organophosphate poisoning. The American journal of emergency medicine. 2006; 24(7): 822-7.
• Senanayake N KL. Neurotoxic effects of organophosphorus insecticides: An intermediate syndrome. N Engl J Med 1987; 316: 761–3.
• Choi P T-L, Quınonez LG, Cook DJ. Acute 0rganophosphate insecticide poisoning. Clinical Intensive Care 1995; 6:5.
• Johnson MK, Jacobsen D, Meredith TJ. Evaluation of antidotes for poisoning by organophosphorus pesticides. Emerg Med. 2000; 12:22–37.
• Connors NJ, Harnett ZH, Hoffman RS. Comparison of current recommended regimens of atropinization in organophosphate poisoning. J Med Toxicol 2014; 10: 143–7.
• Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev. 2003; 22:165–190.
• Samuel J, Thomas K, Jeyaseelan L, Peter JV, Cherian AM. Incidence of intermediate syndrome in organophosphorous poisoning. The Journal of the Association of Physicians of India. 1995; 43(5): 321-3.
• Eddleston M, Eyer P, Worek F, et al. Pralidoxime in acute organophosphorus insecticide poisoning a randomised controlled trial. PLoS medicine. 2009; 6(6): e1000104.
• Lin TJ, Jiang DD, Chan HM, Hung DZ, Li HP. Prognostic factors of organophosphate poisoning between the death and survival groups. The Kaohsiung journal of medical sciences. 2007; 23(4): 176-82.
• Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31:149-62.
• Zhong P, Wang Q, Sheng H. Alteration of banked blood cholinesterase level and its significance in emergency treatment of acute organophosphorus pesticide poisoning. Zhonghua Nei Ke Za Zhi. 2000; 39(10):658-9.
• Qiu HM, Zheng SC, Wan WG, Zou HJ. Meta-analysis of the effectiveness of plasma exchange in treatment of severe and acute organophosphate poisoning. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases. 2011; 29(10): 779-81.
• Bibi S, Kauser S, Ahsan I. Guillain-Barre Syndrome: A Rare Complication of Organophosphate Poisoning. J Coll Physicians Surg Pak. 2022; 32(4): 52-54.
• Lotti M. Clinical toxicology of anticholinesterase agents in humans. In: Krieger R, editor. Handbook of pesticide toxicology. Volume 2. Agents. 2 edn. Academic Press; San Diego: 2001.p.1043–1085.
• Li B, Sedlacek M, Manoharan I. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol. 2005;70:1673–1684.
• Liu H, Kan B, Jian X, Zhang W, Zhou Q, Wang J. Parasuicidal poisoning by intramuscular injection of insecticide: A case report. Experimental and therapeutic medicine. 2013; 6(3): 696-8.
• Li B, Stribley JA, Ticu A, et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem. 2000; 75:1320-1331.
• Ashani Y. Prospective of human butyrilcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev Res 2000; 50:298-308.
• Yilmaz M, Sebe A, Ay MO, et al. Effectiveness of therapeutic plasma exchange in patients with intermediate syndrome due to organophosphate intoxication. The American journal of emergency medicine. 2013; 31(6): 953-7.
• Korach JM, Guillevin L, Petitpas D, Berger P, Chillet P. Apheresis registry in France: indications, techniques, and complications. French Registry Study Group. Therapeutic apheresis: official journal of the International Society for Apheresis and the Japanese Society for Apheresis. 2000; 4(3): 207-10.
• Ring A, Sieber WA, Studt JD, et al. Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care Center. J Clin Med. 2023; 12(8): 2876.
• Norda R, Stegmayr BG. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2003; 29(2): 159-66.
• Lee P, Tai DY. Clinical features of patients with acute organophosphate poisoning requiring intensive care. Intensive Care Med 2001; 27: 694-699.
• Tsai JR, Sheu CC, Cheng MH, et al. Organophosphate poisoning: 10 years of experience in southern Taiwan. Kaohsiung J Med Sci 2007; 23:112-119.
• Eddleston M. The pathophysiology of organophosphorus pesticide self-poisoning is. Fundam Appl Toxicol.1991;17:177-185. Neth J Med 2008; 66:146-148.